Clopixol Depot Adverse Reactions

The most common undesirable effects are dry mouth, somnolence, akathisia, hyperkinesia and hypokinesia, which may occur in more than 10% of treated patients.
Summary of the safety profile: The undesirable effects are, for the majority, dose-dependent. The frequency and severity are most pronounced in the early phase of treatment and decline during continued treatment.
Extrapyramidal reactions may occur, especially in the early phase of treatment. In most cases, these side effects can be satisfactorily controlled by reduction of dosage and/or use of antiparkinsonian drugs. The routine prophylactic use of antiparkinsonian drugs is not recommended. Antiparkinsonian drugs do not alleviate tardive dyskinesia and may aggravate them. Reduction in dosage or, if possible, discontinuation of zuclopenthixol therapy is recommended. In persistent akathisia, a benzodiazepine or propranolol may be beneficial.
Tabulated list of adverse reactions: Frequencies are taken from the literature and spontaneous reporting. Frequencies are defined as: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1000 to <1/100), rare (≥1/10000 to <1/1000), very rare (<1/10000), or not known (cannot be estimated from the available data). (See table.)

Click on icon to see table/diagram/image

Description of selected adverse reactions: As with other drugs belonging to the therapeutic class of antipsychotics, rare cases of QT prolongation, ventricular arrhythmias (ventricular fibrillation and ventricular tachycardia), Torsade de Pointes, cardiac arrest and sudden unexplained death have been reported for zuclopenthixol (see Precautions).
Abrupt discontinuation of zuclopenthixol may be accompanied by withdrawal symptoms. The most common symptoms are nausea, vomiting, anorexia, diarrhoea, rhinorrhoea, sweating, myalgias, paraesthesias, insomnia, restlessness, anxiety, and agitation. Patients may also experience vertigo/dizziness, alternate feelings of warmth and coldness (hot and cold flashes), and tremor. Symptoms generally begin within 1 to 4 days of withdrawal and abate within 7 to 14 days or in 1 to 2 weeks.